The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Jean Yves Reginster

Correspondence to Professor Jean-Yves Reginster

Department of Public Health and Health Economics

University of Liege

4020 Liege

Belgium

[email]@ulg.ac.be

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Correspondence to Professor Jean-Yves Reginster, Department of Public Health and Health Economics, University of Liege, 4020 Liege, Belgium. 1999 - 2013
  • Department of Public Health Sciences, CHU Sart Tilman, University of Liège, Liège, Belgium. 2009 - 2012
  • Bone and Cartilage Metabolism Research Unit, CHU Centre - Ville, Liege, Belgium. 2000 - 2011
  • University of Liège, Public Health and Health Economics, Liège, Belgium. 2001 - 2009
  • Bone and Cartilage Metabolism Research Unit (WHO Collaborating Center for Public Aspects of Osteoarticular Disorders), University of Liege, Belgium. 2001 - 2006
  • University of Liège, Liège, Belgium. 2006
  • Department of Public Health, Epidemiology and Health Economics, University of Liège and the World Health Organization Collaborating Centre for Public Health Aspects of Bone Diseases, Liège, Belgium. 2006
  • CHU Centre-Ville, Liège, Belgium. 2004

References

  1. Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Reginster, J.Y., Badurski, J., Bellamy, N., Bensen, W., Chapurlat, R., Chevalier, X., Christiansen, C., Genant, H., Navarro, F., Nasonov, E., Sambrook, P.N., Spector, T.D., Cooper, C. Ann. Rheum. Dis. (2013) [Pubmed]
  2. Role of glucosamine in the treatment for osteoarthritis. Reginster, J.Y., Neuprez, A., Lecart, M.P., Sarlet, N., Bruyere, O. Rheumatol. Int. (2012) [Pubmed]
  3. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Reginster, J.Y. Drugs (2011) [Pubmed]
  4. Interest of lasofoxifene in the treatment of osteoporosis. Evaluation of "Lasofoxifene in postmenopausal women with osteoporosis". N Engl J Med 2010;362:686-96. Reginster, J.Y. Expert. Opin. Pharmacother (2010) [Pubmed]
  5. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Reginster, J.Y., Bruyère, O., Sawicki, A., Roces-Varela, A., Fardellone, P., Roberts, A., Devogelaer, J.P. Bone (2009) [Pubmed]
  6. Strontium ranelate: new data on fracture prevention and mechanisms of action. Reginster, J.Y., Deroisy, R., Neuprez, A., Hiligsmann, M., Zegels, B., Bruyere, O. Curr. Osteoporos. Rep (2009) [Pubmed]
  7. Ibandronate in profile: drug characteristics and clinical efficacy. Reginster, J.Y., Neuprez, A., Bruyère, O. Expert. Opin. Drug. Metab. Toxicol (2008) [Pubmed]
  8. Injectable bisphosphonates for the treatment of osteoporosis. Reginster, J.Y., Burlet, N., Close, P., Bruyere, O. Womens. Health. (Lond. Engl) (2007) [Pubmed]
  9. Calcium and vitamin D for osteoporotic fracture risk. Reginster, J.Y. Lancet (2007) [Pubmed]
  10. Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis. Reginster, J.Y., Heraud, F., Zegels, B., Bruyere, O. Mini. Rev. Med. Chem (2007) [Pubmed]
  11. Current role of glucosamine in the treatment of osteoarthritis. Reginster, J.Y., Bruyere, O., Neuprez, A. Rheumatology. (Oxford) (2007) [Pubmed]
  12. Strontium ranelate in the prevention of osteoporotic fractures. Reginster, J.Y., Malaise, O., Neuprez, A., Bruyere, O. Int. J. Clin. Pract. (2007) [Pubmed]
  13. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date. Reginster, J.Y., Malaise, O., Neuprez, A., Jouret, V.E., Close, P. Drugs. Aging (2007) [Pubmed]
  14. Patient preference in the management of postmenopausal osteoporosis with bisphosphonates. Reginster, J.Y., Rabenda, V. Clin. Interv. Aging (2006) [Pubmed]
  15. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Reginster, J.Y., Felsenberg, D., Cooper, C., Stakkestad, J.A., Miller, P.D., Kendler, D.L., Adami, S., McClung, M.R., Bolognese, M.A., Civitelli, R., Dumont, E., Bonvoisin, B., Recker, R.R., Delmas, P.D. Osteoporos. Int (2006) [Pubmed]
  16. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Reginster, J.Y., Adami, S., Lakatos, P., Greenwald, M., Stepan, J.J., Silverman, S.L., Christiansen, C., Rowell, L., Mairon, N., Bonvoisin, B., Drezner, M.K., Emkey, R., Felsenberg, D., Cooper, C., Delmas, P.D., Miller, P.D. Ann. Rheum. Dis. (2006) [Pubmed]
  17. Adherence and persistence: impact on outcomes and health care resources. Reginster, J.Y. Bone (2006) [Pubmed]
  18. Osteoporosis: a still increasing prevalence. Reginster, J.Y., Burlet, N. Bone (2006) [Pubmed]
  19. Raloxifene reduces fractures in postmenopausal women with osteoporosis. Reginster, J.Y., Devogelaer, J.P. Clin. Orthop. Relat. Res. (2006) [Pubmed]
  20. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis. Burlet, N., Reginster, J.Y. Clin. Orthop. Relat. Res. (2006) [Pubmed]
  21. Adherence, patient preference and dosing frequency: understanding the relationship. Reginster, J.Y., Rabenda, V., Neuprez, A. Bone (2006) [Pubmed]
  22. Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis. Reginster, J.Y., Gieschke, R. Curr. Drug Metab. (2006) [Pubmed]
  23. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. Reginster, J.Y., Seeman, E., De Vernejoul, M.C., Adami, S., Compston, J., Phenekos, C., Devogelaer, J.P., Curiel, M.D., Sawicki, A., Goemaere, S., Sorensen, O.H., Felsenberg, D., Meunier, P.J. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  24. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. Reginster, J.Y., Wilson, K.M., Dumont, E., Bonvoisin, B., Barrett, J. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  25. Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action. Reginster, J.Y., Sarlet, N., Lejeune, E., Leonori, L. Curr. Osteoporos. Rep (2005) [Pubmed]
  26. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss. Reginster, J.Y., Lecart, M.P., Richy, F. J. Rheumatol. Suppl (2005) [Pubmed]
  27. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. Reginster, J.Y. Expert. Opin. Pharmacother (2005) [Pubmed]
  28. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Reginster, J.Y. Curr. Pharm. Des. (2005) [Pubmed]
  29. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Reginster, J.Y., Sarkar, S., Zegels, B., Henrotin, Y., Bruyere, O., Agnusdei, D., Collette, J. Bone (2004) [Pubmed]
  30. Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities. Reginster, J.Y. J. Intern. Med. (2004) [Pubmed]
  31. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Reginster, J.Y., Lecart, M.P., Deroisy, R., Lousberg, C. Expert. Opin. Investig. Drugs (2004) [Pubmed]
  32. Strontium ranelate: a new paradigm in the treatment of osteoporosis. Reginster, J.Y., Deroisy, R., Jupsin, I. Drugs. Today (2003) [Pubmed]
  33. Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies. Reginster, J.Y., Meunier, P.J. Osteoporos. Int (2003) [Pubmed]
  34. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial. Reginster, J.Y., Felsenberg, D., Pavo, I., Stepan, J., Payer, J., Resch, H., Glüer, C.C., Mühlenbacher, D., Quail, D., Schmitt, H., Nickelsen, T. Osteoporos. Int (2003) [Pubmed]
  35. New perspectives in the management of osteoarthritis. structure modification: facts or fantasy?. Reginster, J.Y., Bruyere, O., Henrotin, Y. J. Rheumatol. Suppl (2003) [Pubmed]
  36. Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. Reginster, J.Y., Bruyere, O., Lecart, M.P., Henrotin, Y. Curr. Opin. Rheumatol (2003) [Pubmed]
  37. Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion. Reginster, J.Y., Zegels, B., Lejeune, E., Micheletti, M.C., Kvsaz, A., Seidel, L., Sarlet, N. Calcif. Tissue Int. (2002) [Pubmed]
  38. Strontium ranelate in osteoporosis. Reginster, J.Y. Curr. Pharm. Des. (2002) [Pubmed]
  39. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Reginster, J.Y., Deroisy, R., Rovati, L.C., Lee, R.L., Lejeune, E., Bruyere, O., Giacovelli, G., Henrotin, Y., Dacre, J.E., Gossett, C. Lancet (2001) [Pubmed]
  40. Intermittent cyclic tiludronate in the treatment of osteoporosis. Reginster, J.Y., Christiansen, C., Roux, C., Fechtenbaum, J., Rouillon, A., Tou, K.P. Osteoporos. Int (2001) [Pubmed]
  41. Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy. Reginster, J.Y., Gillet, P., Gosset, C. Bull. World Health Organ. (2001) [Pubmed]
  42. Evidence of nutriceutical effectiveness in the treatment of osteoarthritis. Reginster, J.Y., Gillot, V., Bruyere, O., Henrotin, Y. Curr. Rheumatol. Rep (2000) [Pubmed]
  43. Direct costs of hip fractures in patients over 60 years of age in Belgium. Reginster, J.Y., Gillet, P., Ben Sedrine, W., Brands, G., Ethgen, O., de Froidmont, C., Gosset, C. Pharmacoeconomics (1999) [Pubmed]
 
WikiGenes - Universities